Adult female mice completing eight weeks of progressive weighted wheel running showed equivalent gains in maximal exercise capacity, grip strength, and myofiber hypertrophy regardless of whether they received rapamycin or not — but both once-weekly and three-times-weekly rapamycin impaired glucose metabolism, with the intermittent schedule producing significantly less disruption than the frequent schedule.
For years, the consensus in both exercise physiology and longevity biology has been quietly damning for the growing cohort of active adults taking rapamycin off-label: the drug blocks mTORC1, the master switch for muscle protein synthesis and skeletal muscle anabolism, and a string of studies using acute resistance exercise models in rodents confirmed that rapamycin administered around exercise sharply blunts the post-workout protein synthetic response. The implication seemed mechanistically watertight — rapamycin and the gym are fundamentally at odds.
A new preprint from the University of Wisconsin-Madison challenges this assumption head-on, and the findings are largely reassuring for active rapamycin users — with one persistent and important caveat.
Researchers led by Elliehausen and Konopka put 5-month-old female C57BL/6J mice through eight weeks of Progressive Weighted Wheel Running, or PoWeR — a voluntary, high-volume paradigm combining endurance and resistance elements in a way that more closely resembles how people actually train than the forced, acute, or surgically-induced models used in prior rapamycin-exercise studies. The mice were simultaneously dosed with either frequent rapamycin (2 mg/kg, three times per week), intermittent rapamycin (2 mg/kg, once per week), or vehicle.
The physical performance finding was unambiguous: rapamycin at neither dosing frequency attenuated improvements in maximal treadmill exercise capacity, all-limb grip strength, or myofiber cross-sectional area after PoWeR. Both dosing schedules produced functional outcomes equivalent to the vehicle group. Intermittent rapamycin mice showed statistically significant Type IIA soleus myofiber hypertrophy relative to sedentary controls, while the vehicle group only trended toward significance — though this likely reflects the fact that intermittent mice accumulated more total running distance, complicating attribution. Critically, frequent rapamycin demonstrably suppressed downstream mTORC1 signaling in tibialis anterior and FDL muscle at 24 hours post-dose, yet this biochemical inhibition failed to translate into blunted fiber growth. This suggests that mTORC1-independent hypertrophic mechanisms — via the MAPK pathway, MYC transcription factors, or mTORC2-dependent synthesis — are doing substantial work in this exercise model.
The less welcome finding is that exercise cannot rescue rapamycin’s well-documented metabolic liability. Frequent dosing (3x/week) increased glucose burden during tolerance testing by 40% relative to exercising vehicle mice, with measurably impaired insulin sensitivity. Once-weekly dosing reduced the glucose disruption to 21% above vehicle — a statistically significant improvement over the frequent schedule, but still not zero. Eight weeks of high-volume voluntary training was not sufficient to normalize glucose homeostasis in either rapamycin group.
For the growing number of physically active adults experimenting with rapamycin for longevity purposes, these data provide the first direct evidence from a voluntary exercise model that rapamycin is largely compatible with the physical adaptations they are training for — while reinforcing that metabolic monitoring and dosing schedule optimization are non-negotiable.
Abstract
An increasing number of physically active adults are taking the mTOR inhibitor rapamycin off label with the goal of extending healthspan. However, frequent rapamycin dosing disrupts metabolic health during sedentary conditions and abates the anabolic response to exercise. Intermittent once weekly rapamycin dosing minimizes many negative metabolic side effects of frequent rapamycin in sedentary mice. However, it remains unknown how different rapamycin dosing schedules impact metabolic, physical, and skeletal muscle adaptations to voluntary exercise training. Therefore, we tested the hypothesis that intermittent rapamycin (2mg/kg; 1x/week) would avoid detrimental effects on adaptations to 8 weeks of progressive weighted wheel running (PoWeR) in adult female mice (5-month-old) by evading the sustained inhibitory effects on mTOR signaling by more frequent dosing schedules (2mg/kg; 3x/week). Frequent but not intermittent rapamycin suppressed skeletal muscle mTORC1 signaling in PoWeR trained mice. PoWeR improved maximal exercise capacity, absolute grip strength, and myofiber hypertrophy with no differences between vehicle or rapamycin treated mice. Conversely, frequent and intermittent rapamycin treated mice had impaired glucose tolerance and insulin sensitivity compared to vehicle treated mice after PoWeR; however, intermittent rapamycin reduced the impact on glucose intolerance versus frequent rapamycin. Collectively, these data in adult female mice suggest that 1) rapamycin is largely compatible with the physical and skeletal muscle benefits of PoWeR and 2) the detrimental effects of rapamycin on body composition and glucose metabolism in the context of voluntary exercise may be reduced by intermittent dosing.